On October 4, 2023 Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, reported that an abstract involving SNAP-CAR has been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 38th Annual Meeting (SITC 2023) (Press release, Coeptis Therapeutics, OCT 4, 2023, View Source [SID1234635659]). SITC (Free SITC Whitepaper) 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation titled, "SNAP CAR T cells for programmable antigen targeting," will detail research involving SNAP-CAR, a "universal" CAR T cell therapy platform that can be adapted to different cancer indications. Licensed by Coeptis from the University of Pittsburgh, SNAP-CAR offers an opportunity to direct the power of CAR T to an array of cancers that have, until now, been inaccessible via current cell therapy technologies by providing a highly programmable antigen targeting platform.

"Having research on SNAP-CAR presented at such a renowned oncology conference as SITC (Free SITC Whitepaper) provides additional validation of the technology’s potential and the exceptional work being conducted by Dr. Lohmueller and his team at the University of Pittsburgh," said Dave Mehalick, President and CEO of Coeptis Therapeutics. "SNAP-CAR represents a powerful technology with the potential to be engineered to address numerous cancers, including HER2-expressing cancer, which we are targeting as our potential first-in-human clinical development program."

About SNAP-CAR
SNAP-CAR, which Coeptis Therapeutics licensed from the University of Pittsburgh, is designed to be a "universal" CAR T cell therapy platform that can be adapted to different cancer indications. Instead of directly binding to a target on the tumor cell, CAR T cells are co-administered with one or more antibody adaptors that bind to the tumor cells and are fitted with a chemical group that irreversibly connects them to the SNAP-CAR on the therapeutic cells via a covalent bond. Pre-clinical studies in mice have demonstrated that by targeting tumors via antibody adaptor molecules, the SNAP-CAR therapy provides a highly programmable therapeutic platform.

On October 4, 2023 Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, reported that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper)-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) (Free AACR-NCI-EORTC Whitepaper) AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) 2023, which is scheduled to be held October 11th – 15th in Boston, Massachusetts (Press release, Beyond Air, OCT 4, 2023, View Source [SID1234635658]). Abstracts are scheduled to be released to AACR (Free AACR Whitepaper)-NCI-EORTC registrants today 12:00 pm U.S. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the Company’s poster presentations are as follows:

Title: Intratumoral Administration of Ultra High-Concentration Nitric Oxide (UNO) and Anti PD-1 Treatment Leads to High Tumor Regression Rates and Prolonged Survival in Tumor-Bearing Mice
Poster number: A078
Session: Poster Session A
Session Date and Time: Thursday, October 12, 2023 / 12:30 pm – 4:00 pm EDT
Session Location: Level 2, Exhibit Hall D
Abstract Number: 35782
Participant: Yana Epshtein, PhD; Head of Translational Science, Beyond Cancer, Ltd.

Title: Ultra-high concentration nitric oxide (UNO) enhances anti-CTLA-4 treatment activity and induces a durable anti-tumor response
Poster number: C080
Session: Poster Session C
Session Date and Time: Saturday, October 14, 2023 / 12:30 pm – 4:00 pm EDT
Session Location: Level 2, Exhibit Hall D
Abstract Number: 35688
Participant: Yogev Sela, PhD; Head of In Vitro Studies, Beyond Cancer, Ltd.

About Nitric Oxide
Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens.

On October 4, 2023 Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, reported the presentation of preliminary 18-month safety and efficacy data from its ongoing Phase 1/2A clinical trial evaluating the safety, tolerability, and signal of efficacy of Radspherin in patients with peritoneal carcinomatosis from colorectal cancer at the 13th International Congress on Peritoneal Surface Malignancies of the Peritoneal Surface Oncology Group International (PSOGI), to be held at the Palazzo del Cinema in Venice, Italy from October 4 – 6, 2023 (Press release, Oncoinvent, OCT 4, 2023, https://www.oncoinvent.com/press-release/oncoinvent-presents-preliminary-18-month-safety-and-efficacy-data-from-ongoing-rad-18-002-phase-1-2a-trial-of-radspherin-in-colorectal-cancer-patients-at-the-13th-psogi-international-congress-on/ [SID1234635657]). The presentation, titled "18-month safety and efficacy after intraperitoneal treatment with 224Radium-labelled microparticles (Radspherin) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for colorectal peritoneal metastasis (PM)" will be presented on October 4, 2023 from 11:55 a.m. to 12:05 p.m. CET (5:55 a.m. EDT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to continue to demonstrate the robust safety and efficacy profile of Radspherin with the presentation of 18-month data at PSOGI. At 18 months, none of the patients administered Radspherin at the recommended dose experienced peritoneal recurrences. Along with a demonstrated robust safety profile, we believe Radspherin has potential as a novel treatment," said Anders Månsson, Chief Executive Officer of Oncoinvent. "These data represent a significant clinical milestone for Radspherin, giving us confidence in its potential to prevent peritoneal recurrence. We look forward to the continued clinical development of this promising therapy."

Details of the oral presentations are as follows:

Oral Presentation Session: Session II Oral Abstract – Colorectal Cancer

Presentation Title: 18-month safety and efficacy after intraperitoneal treatment with 224Radium-labelled microparticles (Radspherin) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for colorectal peritoneal metastasis (PM)

Presenting Author: Stein Gunnar Larsen, MD, PhD, Oslo University Hospital, the Norwegian Radium Hospital.

Oral Presentation Date and Time: October 4th, 2023, from 11:55 a.m. to 12:05 p.m. CET (8:05 a.m. EDT)

This Phase 1/2A study is designed to evaluate the safety, tolerability, and signal of efficacy of Radspherin injected intraperitoneally two days after the completion of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). A dose of 7 MBq was recommended following the completion of dose escalation 1-2-4-7 MBq. A total of 23 patients with peritoneal metastasis from colorectal cancer were enrolled, with 12 receiving the recommended dose of 7MBq. Preliminary safety and survival data at 18-months is presented.

Key results:

At 18 months, none of the 12 patients who received the recommended dose of 7 MBq experienced peritoneal recurrences
Only 2.6% of all adverse events reported were considered to be related to Radspherin, all of which were grade 1-2

Additionally, a poster demonstrating Radspherin as a novel radiopharmaceutical for treatment for peritoneal metastasis will be presented on October 4th, 2023

Poster Presentation Session: Treatment and Prevention of Peritoneal Metastases from Colorectal Cancer

Poster Title: Novel radiopharmaceutical for intraperitoneal treatment of peritoneal metastasis from colorectal and ovarian cancer after complete surgical resection

Presenting Author: Kari Myren, Oncoinvent AS

Poster Presentation Date and Time: October 4th, 2023, from 1:00 p.m. to 1:30 p.m. CET (9:00 a.m. to 9:30 a.m. EDT)

On October 4, 2023 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, reported forthcoming presentations during the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) in Boston, October 11-15, 2023 (Press release, Black Diamond Therapeutics, OCT 4, 2023, View Source [SID1234635656]). The three poster presentations include initial dose escalation data from the Company’s Phase 1 clinical trial of BDTX-1535 in non-small cell lung cancer (NSCLC), the study design of this ongoing Phase 1 clinical trial, and preclinical data for BDTX-4933.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentations are as follows:

Title: Phase 1 Study of BDTX-1535, an Oral 4th Generation EGFR Inhibitor, in Patients with NSCLC and
GBM: Preliminary Dose Escalation Results
Speaker: Helena Yu, M.D., Associate Attending Physician, Memorial Sloan Kettering Cancer Center
Time: Poster Session C, Saturday, October 14, 12:30 pm-4:00 pm
Location/Poster #: Level 2, Exhibit Hall D, #C022

Title: A Phase 1 Study to Assess BDTX-1535, an Oral 4th Generation EGFR Inhibitor, in Patients with NSCLC and GBM
Speaker: Helena Yu, M.D., Associate Attending Physician, Memorial Sloan Kettering Cancer Center
Time: Poster Session C, Saturday, October 14, 12:30 pm-4:00 pm
Location/Poster #: Level 2, Exhibit Hall D, #C036

Title: Preclinical Efficacy of BDTX-4933, a Brain-penetrant, Orthosteric RAF Inhibitor, Targeting Oncogenic RAF Conformation Shared by Groups of BRAF and Upstream Driver Mutations
Speaker: Elizabeth Buck, Ph.D., Chief Scientific Officer, Black Diamond Therapeutics
Time: Poster Session A, Thursday, October 12, 12:30 pm-4:00 pm
Location/Poster #: Level 2, Exhibit Hall D, #A090

About BDTX-1535
BDTX-1535 is a brain-penetrant and potent MasterKey inhibitor of oncogenic mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC), including families of intrinsic driver mutations and acquired resistance C797S mutation that result post-treatment with osimertinib. While current treatments for NSCLC target singular mutations, BDTX-1535 has the potential to address approximately 50 different mutations across a diverse group of patients in multiple lines of therapy. BDTX-1535 also has the potential to treat patients with glioblastoma multiforme (GBM) expressing EGFR alterations. The ongoing BDTX-1535 Phase 1 clinical trial is currently in dose expansion for NSCLC and dose escalation for GBM.

On October 4, 2023 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), reported that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi (Press release, MediciNova, OCT 4, 2023, View Source [SID1234635655]). The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!